Abstract
Dyslipidaemia is commonly observed in patients with active rheumatoid arthritis (RA), with lower total cholesterol levels as well as lower levels of high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) reported in these patients than in individuals without RA. This pattern is mirrored in sepsis and other inflammatory states, suggesting systemic inflammation has the general effect of lowering circulating lipid levels. In line with such observations, suppressing inflammation with DMARDs, biologic therapies and small-molecule Janus kinase inhibitors seems to elevate levels of lipid fractions in RA, albeit in a variable manner dependent presumably upon the mechanism of action of the different agents. In addition, limited epidemiological data in patients with RA suggest increased cardiovascular disease (CVD) risk at relatively low cholesterol levels, a pattern contrasting with that observed in the population without RA. Our understanding of the potential mechanisms behind these inflammation-associated lipid changes remains suboptimal and requires further study. In clinical terms, however, use of the total cholesterol to HDL-C ratio as the lipid component of CVD risk scoring in patients with RA would seem appropriate given that these lipid parameters generally change in parallel with inflammation and suppression of inflammation. Whether alternative lipid or lipoprotein measures (or simple markers of inflammation) could improve stratification of CVD risk in RA beyond the established risk factors requires future investigation.
Key Points
-
Plentiful evidence indicates high-grade inflammation is associated with a reduction in circulating levels of lipids, which is at least partially reversible using anti-inflammatory therapies or with resolution of inflammation
-
Evidence, although limited, suggests that lower cholesterol levels, in the context of high levels of inflammation, are associated with increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA)
-
Different anti-inflammatory therapies seem to increase the levels of high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) to variable degrees, suggesting lipid elevations might be treatment-specific
-
Typically, total cholesterol, LDL-C and HDL-C levels change in the same direction, inversely to changes in inflammation; the total cholesterol:HDL-C ratio seems the most appropriate lipid-associated marker for CVD risk in RA
-
Future studies should determine to what extent treatment-related resolution of inflammation or changes in lipid levels, or other risk factors, independently associate with CVD outcomes; such data are currently lacking
-
Trials that include CVD end points are needed to provide the best evidence for the cardiovascular effects of different treatment modalities in RA; however, such trials are costly and technically challenging
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Meune, C., Touzé, E., Trinquart, L. & Allanore, Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 48, 1309–1313 (2009).
Avina-Zubieta, J. A., Thomas, J., Sasatsafavi, M., Lehman, A. J. & Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 71, 1524–1529 (2012).
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22 (2002).
Shepherd, J. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623–1630 (2002).
Amarenco, P., Labreuche, J., Lavallée, P. & Touboul, P. J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35, 2902–2909 (2004).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998–3007 (2002).
European Society of Cardiology. SCORE Risk Charts. The European cardiovascular disease risk assessment model [online], (2012).
Scottish Intercollegiate Guidelines Network. ASSIGN score. Estimate the risk using ASSIGN score [online], (2008).
ClinRisk Ltd. Welcome to the QRISK®2–12 risk calculator: http://qrisk.org [online], (2012).
Framingham Heart Study. Risk Score Profiles [online], (2013).
The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2009).
Voight, B. et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572–580 (2012).
deLemos, A. S., Wolfe, M. L., Long, C. J., Sivapackianathan, R. & Rader, D. J. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation 106, 1321–1326 (2002).
Barker, P. J. & Rye, K. A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 53, 1755–1766 (2012).
Heldenberg, D. et al. Serum lipids and lipoprotein concentrations in women with rheumatoid arthritis. Clin. Rheumatol. 2, 387–391 (1983).
Lorber, M., Aviram, M., Linn, S., Scharf, Y. & Brook, J. G. Hypocholesterolaemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br. J. Rheumatol. 24, 250–255 (1985).
Lakatos, J. & Hárságyi, A. Serum total, HDL, LDL cholesterol, and triglyceridelevels in patients with rheumatoid arthritis. Clin. Biochem. 23, 93–96 (1988).
Kavanaugh, A. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann. Rheum. Dis. 53, 551–552 (1994).
Yoo, W. H. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J. Rheumatol. 31, 1746–1753 (2004).
Park, Y. B. et al. Lipid profiles in untreated patients with rheumatoid arthritis. J. Rheumatol. 26, 1701–1704 (1999).
White, D., Fayez, S. & Doube, A. Atherogenic lipid profiles in rheumatoid arthritis. N. Z. Med. J. 119, U2125 (2006).
Hurt-Camejo, E. et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum. 44, 2761–2767 (2001).
Chung, C. P. et al. Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis. J. Rheumatol. 37, 1633–1638 (2010).
Peters, M. J. et al. The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int. J. Clin. Prac. 64, 1440–1443 (2010).
van Halm, V. P. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 66, 184–188 (2007).
Myasoedova, E. et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann. Rheum. Dis. 67, 1310–1314 (2010).
Myasoedova, E. et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann. Rheum. Dis. 70, 482–487 (2011).
Liu, Y. et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291, 451–459 (2004).
Khovidhunkit, W. et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45, 1169–1196 (2004).
Ettinger, W. H. et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler. Thromb. 14, 8–13 (1994).
Hashizume, M. & Mihara, M. Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors. Cytokine 58, 424–430 (2012).
Carpentier, Y. A. & Scruel, O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr. Opin. Clin. Nutr. Metab. Care 5, 153–158 (2002).
Kontush, A., Chantepie, S. & Chapman, M. J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23, 1881–1888 (2003).
Charles-Schoeman, C. et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 71, 1157–1162 (2012).
Arts, E. et al. High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study. Arthritis Res. Ther. 14, R166 (2012).
Watanabe, J. et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 64, 1828–1837 (2012).
Dursunog˘lu, D. et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol. Int. 25, 241–245 (2005).
Clarke, R. et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518–2528 (2009).
Park, Y. B. et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am. J. Med. 113, 188–193 (2002).
Boers, M. et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62, 842–845 (2003).
Georgiadis, A. N. et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment—a prospective, controlled study. Arthritis Res. Ther. 8, R32 (2006).
Reiss, A. B. et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 58, 3675–3683 (2008).
Munro, R. et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann. Rheum. Dis. 56, 374–377 (1997).
Morris, S. J. et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res. 63, 530–534 (2011).
Navarro-Millán, I. et al. Changes in lipoproteins associated with treatment with methotrexate or combination therapy in early rheumatoid arthritis: results from the TEAR trial. Arthritis Rheum. http://dx.doi.org/10.1002/art.37916.
Jacobsson, L. T. et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 670–675 (2007).
Dixon, W. G. et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905–2912 (2007).
van Sijl, A. M. et al. The effect of TNF-α blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin. Arthritis Rheum. 41, 393–400 (2011).
Daïen, C. I. et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann. Rheum. Dis. 71, 862–868 (2012).
Allanore, Y., Kahan, A., Sellam, J., Ekindjian, O. G. & Borderie, D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin. Chim. Acta 365, 143–148 (2006).
Popa, C. et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 66, 1503–1507 (2007).
Tam, L. S., Tomlinson, B., Chu, T. T., Li, T. K. & Li, E. K. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 26, 1495–1498 (2007).
van Eijk, I. C. et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade. Arthritis Rheum. 60, 1324–1330 (2009).
Popa, C. et al. Anti-inflammatory therapy with tumour necrosis factor α inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. 68, 868–872 (2009).
Sattar, N. et al. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum. 56, 831–839 (2007).
Nishimoto, N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66, 1162–1167 (2007).
Jones, G. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69, 88–96 (2010).
Maini, R. N. et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54, 2817–2819 (2006).
Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987–997 (2008).
Genovese, M. C. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968–2980 (2008).
Yamanaka, H. et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod. Rheumatol. 21, 122–133 (2011).
Burmester, G. R. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann. Rheum. Dis. 70, 755–759 (2011).
Yazici, Y. et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann. Rheum. Dis. 71, 198–205 (2012).
Gabay, C. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet http://dx.doi.org/10.1016/S0140–6736(13)60250–0.
Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6 MR) Consortium, Hingorani, A. S. & Casas, J. P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379, 1214–1224 (2012).
IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205–1213 (2012).
Kerekes, G. et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin. Rheumatol. 28, 705–710 (2009).
Raterman, H. G. et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann. Rheum. Dis. 72, 560–565 (2013).
US Department of Health & Human Services. US Food and Drug Administration News Release: FDA approves Xeljanz for rheumatoid arthritis [online], (2012).
Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495–507 (2012).
van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508–519 (2012).
Sandborn, W. J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616–624 (2012).
Kremer, J. et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64, 970–981 (2012).
ISRCTN Register. TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis [online], (2008).
US NIH. US National Library of Medicine. A study of roactemra/actemra (tocilizumab) in comparison to etanercept in patients with rheumatoid arthritis and cardiovascular disease risk factors [online], (2013).
Peters, M. J. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69, 325–331 (2010).
Kwaliteitsinstituut voor de Gezondheidszorg CBO & Nederlands Huisartsen Genootschap (NHG). Multidisciplinaire richtlijn cardiovasculair risicomanagement, herziening 2011 [online; Dutch], (2011).
Author information
Authors and Affiliations
Contributions
J. Robertson and N. Sattar contributed to all stages of the preparation of this manuscript for publication. M. J. Peters and I. B. McInnes made a substantial contribution to discussion of content.
Corresponding author
Ethics declarations
Competing interests
I. B. McInnes has received speakers bureau (honouraria) and grant/research support from the following companies: Abbott, BMS, Pfizer and UCB. N. Sattar has acted as a consultant for and has received speakers bureau (honouraria) from the following companies: Astra Zeneca, MSD, Roche and USB. J. Robertson and M. J. Peters declare no competing interests.
Rights and permissions
About this article
Cite this article
Robertson, J., Peters, M., McInnes, I. et al. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9, 513–523 (2013). https://doi.org/10.1038/nrrheum.2013.91
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2013.91
This article is cited by
-
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Nature Reviews Rheumatology (2024)
-
Association between systemic inflammatory response index and left ventricular remodeling and systolic dysfunction in atrial fibrillation patients
BMC Cardiovascular Disorders (2023)
-
Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis
Clinical Reviews in Allergy & Immunology (2023)
-
Retrospective analysis and preliminary laboratory validation of treatment efficacy and blood lipid levels in patients with rheumatoid arthritis
Clinical Rheumatology (2023)
-
Discrepancy in Metabolic Syndrome between Psoriatic Arthritis and Rheumatoid Arthritis: a Direct Comparison of Two Cohorts in One Center
Rheumatology and Therapy (2023)